 Angela Myers
Concepts (358)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 21 | 2022 | 236 | 3.410 |
Why?
| | Vaccination | 11 | 2024 | 70 | 2.990 |
Why?
| | Humans | 78 | 2024 | 6579 | 2.700 |
Why?
| | Communicable Diseases | 4 | 2024 | 9 | 2.470 |
Why?
| | Child | 52 | 2024 | 3193 | 2.370 |
Why?
| | Streptococcal Infections | 5 | 2022 | 19 | 2.280 |
Why?
| | Pediatrics | 10 | 2021 | 173 | 2.240 |
Why?
| | Vaccines | 4 | 2024 | 17 | 2.150 |
Why?
| | Pharyngitis | 5 | 2022 | 15 | 1.930 |
Why?
| | Infant | 28 | 2024 | 1394 | 1.630 |
Why?
| | Child, Preschool | 28 | 2023 | 1476 | 1.620 |
Why?
| | Immunization | 3 | 2024 | 25 | 1.600 |
Why?
| | Male | 34 | 2023 | 3113 | 1.500 |
Why?
| | Female | 35 | 2023 | 3362 | 1.470 |
Why?
| | Fellowships and Scholarships | 7 | 2022 | 16 | 1.370 |
Why?
| | Respiratory Tract Infections | 5 | 2022 | 76 | 1.330 |
Why?
| | Adolescent | 24 | 2024 | 2078 | 1.310 |
Why?
| | Unnecessary Procedures | 3 | 2019 | 13 | 1.280 |
Why?
| | Internship and Residency | 6 | 2023 | 33 | 1.250 |
Why?
| | Haemophilus influenzae type b | 2 | 2017 | 2 | 1.220 |
Why?
| | Haemophilus Infections | 2 | 2017 | 5 | 1.220 |
Why?
| | Quality Improvement | 3 | 2018 | 57 | 1.160 |
Why?
| | Immunization Schedule | 2 | 2024 | 10 | 1.140 |
Why?
| | Specialization | 2 | 2023 | 6 | 1.100 |
Why?
| | Influenza Vaccines | 4 | 2018 | 26 | 1.080 |
Why?
| | Pneumonia | 6 | 2017 | 31 | 1.020 |
Why?
| | Parents | 4 | 2021 | 148 | 0.990 |
Why?
| | Education, Medical, Graduate | 6 | 2023 | 10 | 0.960 |
Why?
| | Child Health | 1 | 2024 | 7 | 0.960 |
Why?
| | Practice Patterns, Physicians' | 4 | 2020 | 81 | 0.950 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2021 | 55 | 0.860 |
Why?
| | Emergency Service, Hospital | 5 | 2020 | 124 | 0.850 |
Why?
| | Erythema | 2 | 2012 | 6 | 0.850 |
Why?
| | United States | 15 | 2024 | 640 | 0.830 |
Why?
| | Microbial Sensitivity Tests | 3 | 2019 | 32 | 0.820 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 6 | 0.800 |
Why?
| | Papillomavirus Vaccines | 1 | 2021 | 6 | 0.800 |
Why?
| | Guideline Adherence | 3 | 2018 | 31 | 0.790 |
Why?
| | Streptococcus pyogenes | 4 | 2022 | 13 | 0.750 |
Why?
| | Clinical Competence | 6 | 2023 | 27 | 0.750 |
Why?
| | Video Recording | 1 | 2020 | 14 | 0.740 |
Why?
| | Hospitalization | 9 | 2023 | 197 | 0.740 |
Why?
| | Patient Education as Topic | 1 | 2020 | 52 | 0.730 |
Why?
| | Communication | 4 | 2024 | 43 | 0.700 |
Why?
| | Staphylococcal Infections | 2 | 2016 | 21 | 0.690 |
Why?
| | Communicable Disease Control | 2 | 2016 | 5 | 0.690 |
Why?
| | Community-Acquired Infections | 4 | 2015 | 9 | 0.660 |
Why?
| | Immunotherapy, Active | 2 | 2015 | 2 | 0.640 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2018 | 7 | 0.640 |
Why?
| | Bacteremia | 3 | 2017 | 25 | 0.630 |
Why?
| | Faculty, Medical | 2 | 2023 | 4 | 0.620 |
Why?
| | Administrative Personnel | 2 | 2021 | 3 | 0.620 |
Why?
| | Feces | 2 | 2015 | 38 | 0.600 |
Why?
| | Amish | 1 | 2017 | 1 | 0.590 |
Why?
| | Epidural Abscess | 1 | 2016 | 1 | 0.580 |
Why?
| | Vancomycin | 3 | 2017 | 17 | 0.580 |
Why?
| | Bacterial Infections | 2 | 2021 | 27 | 0.570 |
Why?
| | Inappropriate Prescribing | 4 | 2022 | 26 | 0.570 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 14 | 0.560 |
Why?
| | Adult | 8 | 2023 | 1139 | 0.560 |
Why?
| | Travel | 1 | 2015 | 7 | 0.550 |
Why?
| | Surveys and Questionnaires | 6 | 2021 | 262 | 0.550 |
Why?
| | Retrospective Studies | 19 | 2022 | 1278 | 0.540 |
Why?
| | Influenza, Human | 4 | 2011 | 60 | 0.540 |
Why?
| | Virus Diseases | 1 | 2015 | 11 | 0.530 |
Why?
| | Hospitals, Pediatric | 9 | 2015 | 178 | 0.500 |
Why?
| | Pandemics | 3 | 2024 | 79 | 0.500 |
Why?
| | Macrolides | 2 | 2013 | 9 | 0.480 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 4 | 0.460 |
Why?
| | Antigens, Bacterial | 2 | 2022 | 9 | 0.450 |
Why?
| | Practice Guidelines as Topic | 3 | 2018 | 96 | 0.450 |
Why?
| | Fever | 4 | 2016 | 27 | 0.440 |
Why?
| | Pruritus | 1 | 2012 | 3 | 0.430 |
Why?
| | Flushing | 1 | 2012 | 4 | 0.430 |
Why?
| | Exanthema | 1 | 2012 | 4 | 0.430 |
Why?
| | Hot Temperature | 1 | 2012 | 5 | 0.420 |
Why?
| | Thyroiditis, Suppurative | 1 | 2011 | 1 | 0.410 |
Why?
| | Eikenella corrodens | 1 | 2011 | 1 | 0.410 |
Why?
| | Viridans Streptococci | 1 | 2011 | 2 | 0.410 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2011 | 4 | 0.410 |
Why?
| | Campylobacter Infections | 1 | 2011 | 2 | 0.400 |
Why?
| | False Positive Reactions | 1 | 2011 | 4 | 0.400 |
Why?
| | Enteral Nutrition | 1 | 2012 | 62 | 0.400 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 9 | 0.400 |
Why?
| | Pilot Projects | 3 | 2021 | 111 | 0.400 |
Why?
| | Pleural Effusion | 1 | 2011 | 5 | 0.400 |
Why?
| | Drainage | 1 | 2011 | 35 | 0.390 |
Why?
| | Personnel, Hospital | 1 | 2010 | 5 | 0.370 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 13 | 0.370 |
Why?
| | Antiviral Agents | 4 | 2023 | 26 | 0.370 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2009 | 11 | 0.360 |
Why?
| | Infant, Newborn | 9 | 2020 | 785 | 0.350 |
Why?
| | Herpes Simplex | 2 | 2020 | 10 | 0.350 |
Why?
| | Ambulatory Care Facilities | 3 | 2020 | 37 | 0.340 |
Why?
| | Empyema, Pleural | 2 | 2021 | 10 | 0.320 |
Why?
| | Missouri | 2 | 2019 | 70 | 0.320 |
Why?
| | Tuberculosis, Gastrointestinal | 1 | 2007 | 1 | 0.320 |
Why?
| | Colitis | 1 | 2007 | 13 | 0.310 |
Why?
| | Crohn Disease | 1 | 2007 | 21 | 0.310 |
Why?
| | Prospective Studies | 4 | 2022 | 520 | 0.310 |
Why?
| | Infectious Disease Medicine | 2 | 2023 | 4 | 0.300 |
Why?
| | Young Adult | 3 | 2022 | 616 | 0.290 |
Why?
| | Length of Stay | 7 | 2021 | 232 | 0.280 |
Why?
| | C-Reactive Protein | 2 | 2016 | 16 | 0.280 |
Why?
| | Ankle Injuries | 1 | 2005 | 1 | 0.280 |
Why?
| | Foot Injuries | 1 | 2005 | 1 | 0.280 |
Why?
| | Cephalosporins | 2 | 2017 | 15 | 0.270 |
Why?
| | Cross Infection | 2 | 2015 | 12 | 0.260 |
Why?
| | International Classification of Diseases | 2 | 2015 | 9 | 0.250 |
Why?
| | Treatment Outcome | 7 | 2018 | 633 | 0.250 |
Why?
| | Antibodies, Viral | 2 | 2022 | 46 | 0.250 |
Why?
| | Urinary Tract Infections | 3 | 2016 | 17 | 0.240 |
Why?
| | Trust | 2 | 2021 | 4 | 0.240 |
Why?
| | Educational Status | 1 | 2024 | 20 | 0.240 |
Why?
| | Decision Making | 3 | 2018 | 22 | 0.230 |
Why?
| | Prescriptions | 1 | 2022 | 9 | 0.220 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 46 | 0.220 |
Why?
| | Curriculum | 1 | 2022 | 19 | 0.220 |
Why?
| | Coinfection | 1 | 2022 | 5 | 0.220 |
Why?
| | Competency-Based Education | 4 | 2023 | 5 | 0.210 |
Why?
| | Anti-Infective Agents | 2 | 2015 | 21 | 0.200 |
Why?
| | Feedback | 1 | 2021 | 4 | 0.200 |
Why?
| | Radiography | 3 | 2014 | 49 | 0.200 |
Why?
| | Attitude of Health Personnel | 2 | 2012 | 39 | 0.200 |
Why?
| | Thrombolytic Therapy | 1 | 2021 | 6 | 0.200 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 19 | 0.200 |
Why?
| | Bed Occupancy | 2 | 2011 | 3 | 0.190 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2020 | 15 | 0.190 |
Why?
| | Electronic Health Records | 2 | 2019 | 61 | 0.190 |
Why?
| | Immunization Programs | 2 | 2010 | 6 | 0.190 |
Why?
| | Mandatory Programs | 2 | 2010 | 2 | 0.180 |
Why?
| | Ambulatory Care | 1 | 2020 | 45 | 0.180 |
Why?
| | Inservice Training | 1 | 2019 | 2 | 0.180 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 77 | 0.180 |
Why?
| | Incidence | 2 | 2017 | 128 | 0.180 |
Why?
| | Financial Management | 1 | 2019 | 1 | 0.180 |
Why?
| | Decision Support Systems, Clinical | 1 | 2019 | 17 | 0.170 |
Why?
| | Genetic Variation | 1 | 2020 | 163 | 0.170 |
Why?
| | Cohort Studies | 4 | 2015 | 262 | 0.170 |
Why?
| | Patient-Centered Care | 1 | 2018 | 16 | 0.170 |
Why?
| | Psychometrics | 1 | 2018 | 30 | 0.160 |
Why?
| | Middle Aged | 1 | 2020 | 613 | 0.160 |
Why?
| | Acyclovir | 1 | 2018 | 1 | 0.160 |
Why?
| | Health Communication | 1 | 2018 | 4 | 0.160 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2018 | 3 | 0.160 |
Why?
| | DNA, Viral | 1 | 2018 | 13 | 0.160 |
Why?
| | Central Nervous System Infections | 1 | 2018 | 5 | 0.160 |
Why?
| | Professional Competence | 1 | 2018 | 3 | 0.160 |
Why?
| | Post-Exposure Prophylaxis | 1 | 2017 | 1 | 0.160 |
Why?
| | Rifampin | 1 | 2017 | 7 | 0.160 |
Why?
| | Meningitis, Bacterial | 1 | 2017 | 4 | 0.160 |
Why?
| | Program Evaluation | 2 | 2015 | 44 | 0.160 |
Why?
| | Orbital Cellulitis | 1 | 2017 | 4 | 0.160 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 35 | 0.150 |
Why?
| | Ileitis | 1 | 2017 | 3 | 0.150 |
Why?
| | Clostridium Infections | 1 | 2017 | 7 | 0.150 |
Why?
| | Haemophilus Vaccines | 1 | 2017 | 2 | 0.150 |
Why?
| | Multilocus Sequence Typing | 1 | 2017 | 3 | 0.150 |
Why?
| | Neck Pain | 1 | 2016 | 1 | 0.150 |
Why?
| | Nocturia | 1 | 2016 | 1 | 0.150 |
Why?
| | Staphylococcus epidermidis | 1 | 2016 | 2 | 0.150 |
Why?
| | Leukocytosis | 1 | 2016 | 2 | 0.150 |
Why?
| | Tachycardia | 1 | 2016 | 3 | 0.150 |
Why?
| | Leg | 1 | 2016 | 4 | 0.150 |
Why?
| | Laminectomy | 1 | 2016 | 5 | 0.150 |
Why?
| | Debridement | 1 | 2016 | 5 | 0.150 |
Why?
| | Pediatric Nurse Practitioners | 1 | 2016 | 4 | 0.140 |
Why?
| | Practice Patterns, Nurses' | 1 | 2016 | 5 | 0.140 |
Why?
| | Professional-Family Relations | 1 | 2016 | 9 | 0.140 |
Why?
| | Education, Nursing, Continuing | 1 | 2016 | 3 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2017 | 41 | 0.140 |
Why?
| | Headache | 1 | 2016 | 14 | 0.140 |
Why?
| | Child Health Services | 1 | 2016 | 24 | 0.140 |
Why?
| | Severity of Illness Index | 2 | 2014 | 144 | 0.140 |
Why?
| | Pain | 1 | 2016 | 55 | 0.140 |
Why?
| | Mycobacterium chelonae | 1 | 2016 | 1 | 0.140 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2016 | 2 | 0.140 |
Why?
| | Travel Medicine | 1 | 2015 | 1 | 0.140 |
Why?
| | Developing Countries | 1 | 2015 | 5 | 0.140 |
Why?
| | Hospitalists | 1 | 2015 | 7 | 0.140 |
Why?
| | Drug Utilization | 1 | 2015 | 13 | 0.130 |
Why?
| | Leukocyte Count | 1 | 2015 | 6 | 0.130 |
Why?
| | Statistics as Topic | 1 | 2015 | 19 | 0.130 |
Why?
| | Time Factors | 1 | 2016 | 254 | 0.130 |
Why?
| | Gastrostomy | 1 | 2016 | 62 | 0.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 60 | 0.130 |
Why?
| | Medication Therapy Management | 1 | 2015 | 8 | 0.130 |
Why?
| | Enterovirus B, Human | 1 | 2015 | 1 | 0.130 |
Why?
| | Clinical Laboratory Services | 1 | 2015 | 2 | 0.130 |
Why?
| | Economics, Hospital | 1 | 2015 | 3 | 0.130 |
Why?
| | Microbiological Techniques | 1 | 2015 | 5 | 0.130 |
Why?
| | Cost Savings | 1 | 2015 | 10 | 0.130 |
Why?
| | Ceftriaxone | 1 | 2015 | 13 | 0.130 |
Why?
| | Patient Discharge | 1 | 2015 | 57 | 0.130 |
Why?
| | Sepsis | 1 | 2015 | 22 | 0.130 |
Why?
| | Health Care Surveys | 2 | 2015 | 33 | 0.120 |
Why?
| | Crowding | 2 | 2011 | 4 | 0.120 |
Why?
| | Patient Admission | 2 | 2014 | 10 | 0.120 |
Why?
| | Biological Transport | 1 | 2024 | 17 | 0.120 |
Why?
| | Enterovirus Infections | 1 | 2015 | 37 | 0.120 |
Why?
| | Vancomycin Resistance | 1 | 2014 | 4 | 0.120 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 6 | 0.120 |
Why?
| | Fluoroquinolones | 1 | 2013 | 3 | 0.120 |
Why?
| | Penicillins | 1 | 2013 | 8 | 0.120 |
Why?
| | Staphylococcus aureus | 1 | 2014 | 18 | 0.120 |
Why?
| | Accreditation | 2 | 2023 | 4 | 0.120 |
Why?
| | Medical Records | 1 | 2013 | 13 | 0.120 |
Why?
| | Bacteria | 1 | 2013 | 9 | 0.120 |
Why?
| | Prevalence | 1 | 2013 | 146 | 0.110 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 312 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 2 | 2017 | 123 | 0.110 |
Why?
| | Klebsiella Infections | 1 | 2012 | 3 | 0.110 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2012 | 4 | 0.110 |
Why?
| | Enterobacteriaceae Infections | 1 | 2012 | 10 | 0.110 |
Why?
| | Amine Oxidase (Copper-Containing) | 1 | 2012 | 6 | 0.110 |
Why?
| | Syndrome | 1 | 2012 | 34 | 0.110 |
Why?
| | Gastroparesis | 1 | 2012 | 4 | 0.110 |
Why?
| | Physicians | 1 | 2012 | 23 | 0.110 |
Why?
| | Histamine | 1 | 2012 | 13 | 0.110 |
Why?
| | Gastric Bypass | 1 | 2012 | 8 | 0.110 |
Why?
| | Edema | 1 | 2011 | 7 | 0.100 |
Why?
| | Neck | 1 | 2011 | 5 | 0.100 |
Why?
| | Hospital Administration | 1 | 2011 | 1 | 0.100 |
Why?
| | Clinical Coding | 1 | 2011 | 2 | 0.100 |
Why?
| | Hospital Charges | 1 | 2011 | 11 | 0.100 |
Why?
| | Campylobacter | 1 | 2011 | 2 | 0.100 |
Why?
| | Efficiency, Organizational | 1 | 2011 | 3 | 0.100 |
Why?
| | Immunoassay | 1 | 2011 | 8 | 0.100 |
Why?
| | Diarrhea | 1 | 2011 | 18 | 0.100 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2011 | 1 | 0.100 |
Why?
| | Inpatients | 1 | 2011 | 42 | 0.100 |
Why?
| | Risk Factors | 1 | 2012 | 471 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2011 | 326 | 0.090 |
Why?
| | Patient Transfer | 1 | 2010 | 8 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 342 | 0.090 |
Why?
| | Bacterial Proteins | 1 | 2009 | 8 | 0.090 |
Why?
| | Delphi Technique | 2 | 2018 | 10 | 0.080 |
Why?
| | Radiography, Abdominal | 1 | 2007 | 1 | 0.080 |
Why?
| | Ciprofloxacin | 1 | 2007 | 3 | 0.080 |
Why?
| | Emigrants and Immigrants | 1 | 2007 | 2 | 0.080 |
Why?
| | Helicobacter pylori | 1 | 2007 | 4 | 0.080 |
Why?
| | Helicobacter Infections | 1 | 2007 | 4 | 0.080 |
Why?
| | Mexico | 1 | 2007 | 5 | 0.080 |
Why?
| | Antitubercular Agents | 1 | 2007 | 6 | 0.080 |
Why?
| | Anastomosis, Surgical | 1 | 2007 | 22 | 0.080 |
Why?
| | Vomiting | 1 | 2007 | 23 | 0.080 |
Why?
| | Colectomy | 1 | 2007 | 13 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 146 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2018 | 191 | 0.080 |
Why?
| | Abdominal Pain | 1 | 2007 | 64 | 0.070 |
Why?
| | Appendectomy | 1 | 2007 | 103 | 0.070 |
Why?
| | Physical Examination | 1 | 2005 | 4 | 0.070 |
Why?
| | Dengue Virus | 1 | 2005 | 1 | 0.070 |
Why?
| | Influenza in Birds | 1 | 2005 | 1 | 0.070 |
Why?
| | Pertussis Vaccine | 1 | 2005 | 1 | 0.070 |
Why?
| | Vaccines, Conjugate | 1 | 2005 | 1 | 0.070 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2005 | 2 | 0.070 |
Why?
| | Meningococcal Vaccines | 1 | 2005 | 2 | 0.070 |
Why?
| | Papillomaviridae | 1 | 2005 | 2 | 0.070 |
Why?
| | Malaria Vaccines | 1 | 2005 | 2 | 0.070 |
Why?
| | Vaccines, Inactivated | 1 | 2005 | 2 | 0.070 |
Why?
| | Chickenpox Vaccine | 1 | 2005 | 2 | 0.070 |
Why?
| | Vaccines, Attenuated | 1 | 2005 | 8 | 0.070 |
Why?
| | Birds | 1 | 2005 | 2 | 0.070 |
Why?
| | Pneumococcal Vaccines | 1 | 2005 | 4 | 0.070 |
Why?
| | Infection Control | 1 | 2005 | 7 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 41 | 0.070 |
Why?
| | Viral Vaccines | 1 | 2005 | 10 | 0.070 |
Why?
| | Patient Selection | 1 | 2005 | 32 | 0.070 |
Why?
| | Rotavirus Vaccines | 1 | 2005 | 13 | 0.070 |
Why?
| | AIDS Vaccines | 1 | 2005 | 18 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 43 | 0.070 |
Why?
| | Language | 1 | 2023 | 4 | 0.060 |
Why?
| | Palivizumab | 1 | 2023 | 7 | 0.060 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2023 | 18 | 0.060 |
Why?
| | Animals | 1 | 2005 | 674 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 34 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2022 | 14 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2022 | 18 | 0.060 |
Why?
| | Qualitative Research | 1 | 2022 | 21 | 0.060 |
Why?
| | Immunity, Humoral | 1 | 2022 | 14 | 0.060 |
Why?
| | Schools | 1 | 2023 | 49 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2013 | 72 | 0.050 |
Why?
| | Saliva | 1 | 2021 | 10 | 0.050 |
Why?
| | Patient Handoff | 1 | 2021 | 4 | 0.050 |
Why?
| | Specimen Handling | 1 | 2021 | 17 | 0.050 |
Why?
| | Algorithms | 2 | 2013 | 104 | 0.050 |
Why?
| | Nasopharynx | 1 | 2021 | 25 | 0.050 |
Why?
| | Linear Models | 1 | 2021 | 55 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2021 | 29 | 0.050 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.050 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 38 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2021 | 33 | 0.050 |
Why?
| | Thoracostomy | 1 | 2021 | 8 | 0.050 |
Why?
| | Complement C6 | 1 | 2020 | 4 | 0.050 |
Why?
| | Complement C7 | 1 | 2020 | 4 | 0.050 |
Why?
| | RNA Nucleotidyltransferases | 1 | 2020 | 4 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2020 | 4 | 0.050 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2020 | 4 | 0.050 |
Why?
| | Perforin | 1 | 2020 | 4 | 0.050 |
Why?
| | Scavenger Receptors, Class A | 1 | 2020 | 5 | 0.050 |
Why?
| | GRB2 Adaptor Protein | 1 | 2020 | 5 | 0.050 |
Why?
| | STAT1 Transcription Factor | 1 | 2020 | 6 | 0.050 |
Why?
| | Toll-Like Receptor 3 | 1 | 2020 | 6 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 31 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 37 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2020 | 45 | 0.050 |
Why?
| | Outpatients | 1 | 2020 | 27 | 0.050 |
Why?
| | Pregnancy | 1 | 2020 | 188 | 0.050 |
Why?
| | Educational Measurement | 1 | 2018 | 5 | 0.040 |
Why?
| | Translations | 1 | 2018 | 4 | 0.040 |
Why?
| | Cooperative Behavior | 1 | 2018 | 22 | 0.040 |
Why?
| | Patient Participation | 1 | 2018 | 15 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 17 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2018 | 40 | 0.040 |
Why?
| | Research Design | 1 | 2018 | 58 | 0.040 |
Why?
| | Primary Health Care | 1 | 2018 | 41 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2018 | 33 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 55 | 0.040 |
Why?
| | Biomarkers | 1 | 2018 | 126 | 0.040 |
Why?
| | Patient Readmission | 1 | 2017 | 67 | 0.040 |
Why?
| | Physicians' Offices | 1 | 2016 | 1 | 0.040 |
Why?
| | Sinusitis | 1 | 2016 | 5 | 0.040 |
Why?
| | Soft Tissue Infections | 1 | 2016 | 11 | 0.040 |
Why?
| | Otitis Media | 1 | 2016 | 6 | 0.040 |
Why?
| | Drug Utilization Review | 1 | 2015 | 6 | 0.030 |
Why?
| | Safety Management | 1 | 2015 | 6 | 0.030 |
Why?
| | Cost Control | 1 | 2015 | 1 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 4 | 0.030 |
Why?
| | Health Information Systems | 1 | 2015 | 5 | 0.030 |
Why?
| | Urinalysis | 1 | 2015 | 5 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2015 | 8 | 0.030 |
Why?
| | Poliovirus | 1 | 2015 | 1 | 0.030 |
Why?
| | Databases, Factual | 1 | 2015 | 106 | 0.030 |
Why?
| | Critical Care | 1 | 2014 | 12 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2014 | 16 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2013 | 2 | 0.030 |
Why?
| | Propensity Score | 1 | 2013 | 8 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 16 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 9 | 0.030 |
Why?
| | Logistic Models | 1 | 2013 | 86 | 0.030 |
Why?
| | Reference Standards | 1 | 2013 | 15 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2012 | 14 | 0.030 |
Why?
| | Escherichia coli | 1 | 2012 | 28 | 0.030 |
Why?
| | Models, Organizational | 1 | 2011 | 7 | 0.030 |
Why?
| | Sex Distribution | 1 | 2011 | 17 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2011 | 18 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 31 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 43 | 0.020 |
Why?
| | Comorbidity | 1 | 2011 | 56 | 0.020 |
Why?
| | Risk Assessment | 1 | 2011 | 131 | 0.020 |
Why?
| | Health Facility Size | 1 | 2010 | 1 | 0.020 |
Why?
| | Hospital Information Systems | 1 | 2010 | 1 | 0.020 |
Why?
| | Hospital Bed Capacity | 1 | 2010 | 3 | 0.020 |
Why?
| | Fear | 1 | 2010 | 17 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2010 | 30 | 0.020 |
Why?
| | Influenza B virus | 1 | 2010 | 22 | 0.020 |
Why?
| | Influenza A virus | 1 | 2010 | 20 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|